As filed with the Securities and Exchange Commission on March 1, 2013

Registration No. 333-184625

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 2

TO

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

MusclePharm Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   2834   77-0664193

(State or other jurisdiction

of incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

4721 Ironton Street, Building A

Denver, Colorado 80239

Telephone: (303) 396-6100

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Brad J. Pyatt

Co-Chairman, Chief Executive Officer and President

MusclePharm Corporation

5348 Vegas Drive

Las Vegas, Nevada 89108

Telephone: (702) 953-1890

(Name, address, including zip code, and telephone number, including area code, of agent for service)

  

Copies to:

Reid A. Godbolt, Esq.

Jones & Keller, P.C.

1999 Broadway, Suite 3150

Denver, Colorado 80202

Telephone: (303) 573-1600

Facsimile: (303) 573-8133

 

Harvey J. Kesner, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Telephone: (212) 930-9700

Fax: (212) 930-9725

 

Approximate date of commencement of proposed sale to the public:

As soon as practicable after this Registration Statement is declared effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box:  x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer   o Accelerated filer  o
Non-accelerated filer     o (Do not check if a smaller reporting company) Smaller reporting company  x

 

 
 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment No. 2 (this “Amendment”) is filed pursuant to Rule 462(d) of the Securities Act of 1933, as amended (the “Securities Act”), solely to add exhibits to the Registration Statement on Form S-1, as amended (Registration No. 333-184625) (the “Registration Statement”) of MusclePharm Corporation. Accordingly, this Amendment consists solely of the facing page, this explanatory note, an amended and restated “Item 16. Exhibits and Financial Statement Schedules” section of the Registration Statement, the XBRL interactive data files and the signature page. This filing does not modify any provision of the Registration Statement except as specifically noted herein.

 

The Registration Statement included certain financial information. The XBRL interactive data files that correspond to the financial information presented in the Registration Statement filed on January 16, 2013 are attached as Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB and 101.PRE to this Amendment and incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 
 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16. Exhibits and Financial Statement Schedules

 

        Incorporated by Reference        
Exhibit No.   Description   Form   SEC File No.   Exhibit   Filing Date   Filed Herewith   Furnished Herewith
                             
1.1   Placement Agent Agreement.   8-K   000-53166   1.1   January 23, 2013        
                             
2.1   Agreement Concerning the Exchange of Securities by and Among Tone in Twenty and Muscle Pharm, LLC and the Security Holders of Muscle Pharm, LLC, dated February 1, 2010.   8-K   000-53166   2.1   February 2, 2010        
                             
3.1   Articles of Incorporation of MusclePharm Corporation (successor to Tone In Twenty).   SB-2   333-147111   3.1   November 2, 2007        
                             
3.2   Bylaws of MusclePharm Corporation (successor to Tone In Twenty). (Amended on March 1, 2010 to change fiscal year end to December 31 – set forth on Form 8-K filed on 03-03-2010.)   SB-2   333-147111   3.2   November 2, 2007        
                             
3.3   Amendment to the Articles of Incorporation.   SB-2   333-147111   3.3   November 2, 2007        
                             
3.4   Amendment to the Articles of Incorporation   8-K   000-53166   3.3   February 24, 2010        
                             
3.5   Certificate of Designation relating to the Series A Convertible Preferred Stock.   8-K   000-53166   3.4   February 24, 2010        
                             
3.6   Amendment to the Articles of Incorporation.   10-Q   000-53166   3.1   May 23, 2011        
                             
3.7   Certificate of Designation of Series B Convertible Preferred Stock.   10-Q   000-53166   3.1   August 16, 2011        
                             
3.8   Certificate of Designation of Series C Convertible Preferred Stock.   8-K   000-53166   3.1   November 4, 2011        
                             
3.9   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   November 23, 2011        
                             
3.10   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   January 27, 2012        
                             
3.11   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   March 30, 2012        
                             
3.12   Certificate of Change.   8-K   000-53166   3.1   November 28, 2012        
                             
3.13   Certificate of Amendment to Articles of Incorporation.   8-K   000-53166   3.2   November 28, 2012        
                             
3.14   Certificate of Designation of Series D Convertible Preferred Stock.   8-K   000-53166   3.1   January 17, 2013        
                             
3.15   Certificate of Correction.   S-1/A   333-184625   3.15   December 26, 2012        
                             
4.1   Specimen of certificate for MusclePharm Corporation Series D Convertible Preferred Stock.   8-K   000-53166   4.1   January 28, 2013        
                             
4.2   Specimen of certificate for MusclePharm Corporation Common Stock.   S-1/A   333-184625   4.4   December 28, 2012        
                             
4.3   Form of Promissory Note, dated July 13, 2012, issued by MusclePharm Corporation in favor of TCA Global Credit Master Fund LP.   8-K   000-53166   4.1   July 20, 2012        

 

 
 

 

4.4   Form of Promissory Note.   8-K   000-53166   4.2   December 10, 2012        
                             
5.1   Opinion of Brownstein Hyatt Farber Schreck, LLP.   8-K   000-53166   5.1   January 28, 2013        
                             
10.1   Purchasing Agreement with General Nutrition Corporation dated December 16, 2009.   8-K   000-53166   10.2   February 24, 2010        
                             
10.2   Order Approving Stipulation for Settlement of Claim, dated December 8, 2010, between MusclePharm Corporation and Socius CG II, Ltd.   8-K   000-53166   10.1   December 9, 2010        
                             
10.3   Endorsement Agreement, dated July 20, 2011, between MusclePharm Corporation and Michael Vick, individually.   8-K   000-53166   10.1   July 22, 2011        
                             
10.4   Convertible Promissory Note between MusclePharm Corporation and Brad J. Pyatt, dated November 18, 2010.   S-1/A   333-176771   4.2   September 27, 2011        
                             
10.5   Convertible Promissory Note between MusclePharm Corporation and Brad J. Pyatt, dated November 23, 2010.   S-1/A   333-176771   4.3   September 27, 2011        
                             
10.6   Amended and Restated Employment Agreement, dated November 14, 2011, between MusclePharm Corporation and Brad J. Pyatt.   10-Q   000-53166   10.6   November 14, 2011        
                             
10.7   Amended and Restated Employment Agreement, dated November 14, 2011, between MusclePharm Corporation and Cory J. Gregory.   10-Q   000-53166   10.7   November 14, 2011        
                             
10.8   Employment Agreement, dated September 15, 2011, by and between MusclePharm Corporation and John H. Bluher.   10-Q   000-53166   10.4   November 14, 2011        
                             
10.9   Employment Agreement, dated November 14, 2011, by and between MusclePharm Corporation and Jeremy R. DeLuca.   10-Q   000-53166   10.5   November 14, 2011        
                             
10.10   Securities Purchase Agreement, dated July 10, 2012, between MusclePharm Corporation and Subscribers set forth therein.   8-K   000-53166   10.1   July 19, 2012        
                             
10.11   Consulting Agreement, dated July 12, 2012, between MusclePharm Corporation and Melechdavid, Inc.   8-K   000-53166   10.2   July 19, 2012        
                             
10.12   Consulting Agreement, dated July 12, 2012, between MusclePharm Corporation and GRQ Consultants, Inc.   8-K   000-53166   10.3   July 19, 2012        
                             
10.13   Form of Committed Equity Facility Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        
                             
10.14   Form of Registration Rights Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        
                             
10.15   Form of Security Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        

 

 
 

 

10.16   Form of Indemnification Agreement.   8-K   000-53166   10.1   August 27, 2012        
                             
10.17   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Brad J. Pyatt.   8-K   000-53166   10.1   October 23, 2012        
                             
10.18   Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and L. Gary Davis.   8-K   000-53166   10.2   October 23, 2012        
                             
10.19   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and John H. Bluher.   8-K   000-53166   10.3   October 23, 2012        
                             
10.20   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Jeremy R. DeLuca.   8-K   000-53166   10.4   October 23, 2012        
                             
10.21   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Cory J. Gregory.   8-K   000-53166   10.5   October 23, 2012        
                             
10.22   Form of Restricted Stock Unit Award.   8-K   000-53166   10.1   November 21, 2012        
                             
10.23   Subscription Agreement dated November 30, 2012 between MusclePharm Corporation and the subscribers listed therein.   8-K   000-53166   10.1   December 10, 2012        
                             
10.24   Form of Escrow Agreement.   POS AM   333-184625   10.24   January 8, 2013        
                             
10.25   Form of Subscription Agreement.   8-K   000-53166   10.1   January 28, 2013        
                             
21   Subsidiary of the Registrant.   S-1   333-184625   21   October 26, 2012        
                             
23.1   Consent of Berman & Company, P.A.   POS AM   333-184625   23.1   January 16, 2013        
                             
23.2   Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).   8-K   000-53166   5.1   January 28, 2013        
                             
24.1   Power of Attorney.   S-1/A   333-184625       December 19, 2012        
                             
101.INS   INS XBRL Instance Document.                       X
                             
101.SCH   SCH XBRL Schema Document.                       X
                             
101.CAL   CAL XBRL Calculation Linkbase Document.                       X
                             
101.DEF   DEF XBRL Definition Linkbase Document.                       X
                             
101.LAB   LAB XBRL Label Linkbase Document.                       X
                             
101.PRE   PRE XBRL Presentation Linkbase Document.                       X

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Denver, State of Colorado, on March 1, 2013.

 

  MUSCLEPHARM CORPORATION
       
  By: 

 

/s/ Brad J. Pyatt

 
  Name:  Brad J. Pyatt  
  Title:  Chief Executive Officer and President  
    (Principal Executive Officer)  
       

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Brad J. Pyatt       March 1, 2013
         
   

Co-Chairman, Chief Executive Officer, President and

Principal Executive Officer

   
Brad J. Pyatt    

 

/s/ L. Gary Davis

      March 1, 2013
   

Chief Financial Officer, Principal Financial Officer and

Principal Accounting Officer

   
L. Gary Davis    

 

/s/ John H. Bluher

      March 1, 2013
         
John H. Bluher   Co-Chairman, Executive Vice President and Chief Operating Officer  

 

*

      March 1, 2013
         
Donald W. Prosser   Director  
         

 

*

      March 1, 2013
Michael J. Doron   Director  
         
*       March 1, 2013
James J. Greenwell   Director  
         

 

* By: /s/ Brad J. Pyatt  
    Brad J. Pyatt, Attorney-in-Fact  
       
       

 

 
 

 

EXHIBIT INDEX

 

        Incorporated by Reference        
Exhibit No.   Description   Form   SEC File No.   Exhibit   Filing Date   Filed Herewith   Furnished Herewith
                             
1.1   Placement Agent Agreement.   8-K   000-53166   1.1   January 23, 2013        
                             
2.1   Agreement Concerning the Exchange of Securities by and Among Tone in Twenty and Muscle Pharm, LLC and the Security Holders of Muscle Pharm, LLC, dated February 1, 2010.   8-K   000-53166   2.1   February 2, 2010        
                             
3.1   Articles of Incorporation of MusclePharm Corporation (successor to Tone In Twenty).   SB-2   333-147111   3.1   November 2, 2007        
                             
3.2   Bylaws of MusclePharm Corporation (successor to Tone In Twenty). (Amended on March 1, 2010 to change fiscal year end to December 31 – set forth on Form 8-K filed on 03-03-2010.)   SB-2   333-147111   3.2   November 2, 2007        
                             
3.3   Amendment to the Articles of Incorporation.   SB-2   333-147111   3.3   November 2, 2007        
                             
3.4   Amendment to the Articles of Incorporation   8-K   000-53166   3.3   February 24, 2010        
                             
3.5   Certificate of Designation relating to the Series A Convertible Preferred Stock.   8-K   000-53166   3.4   February 24, 2010        
                             
3.6   Amendment to the Articles of Incorporation.   10-Q   000-53166   3.1   May 23, 2011        
                             
3.7   Certificate of Designation of Series B Convertible Preferred Stock.   10-Q   000-53166   3.1   August 16, 2011        
                             
3.8   Certificate of Designation of Series C Convertible Preferred Stock.   8-K   000-53166   3.1   November 4, 2011        
                             
3.9   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   November 23, 2011        
                             
3.10   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   January 27, 2012        
                             
3.11   Amendment to the Articles of Incorporation.   8-K   000-53166   3.1   March 30, 2012        
                             
3.12   Certificate of Change.   8-K   000-53166   3.1   November 28, 2012        
                             
3.13   Certificate of Amendment to Articles of Incorporation.   8-K   000-53166   3.2   November 28, 2012        
                             
3.14   Certificate of Designation of Series D Convertible Preferred Stock.   8-K   000-53166   3.1   January 17, 2013        
                             
3.15   Certificate of Correction.   S-1/A   333-184625   3.15   December 26, 2012        
                             
4.1   Specimen of certificate for MusclePharm Corporation Series D Convertible Preferred Stock.   8-K   000-53166   4.1   January 28, 2013        
                             
4.2   Specimen of certificate for MusclePharm Corporation Common Stock.   S-1/A   333-184625   4.4   December 28, 2012        
                             
4.3   Form of Promissory Note, dated July 13, 2012, issued by MusclePharm Corporation in favor of TCA Global Credit Master Fund LP.   8-K   000-53166   4.1   July 20, 2012        

 

 
 

 

4.4   Form of Promissory Note.   8-K   000-53166   4.2   December 10, 2012        
                             
5.1   Opinion of Brownstein Hyatt Farber Schreck, LLP.   8-K   000-53166   5.1   January 28, 2013        
                             
10.1   Purchasing Agreement with General Nutrition Corporation dated December 16, 2009.   8-K   000-53166   10.2   February 24, 2010        
                             
10.2   Order Approving Stipulation for Settlement of Claim, dated December 8, 2010, between MusclePharm Corporation and Socius CG II, Ltd.   8-K   000-53166   10.1   December 9, 2010        
                             
10.3   Endorsement Agreement, dated July 20, 2011, between MusclePharm Corporation and Michael Vick, individually.   8-K   000-53166   10.1   July 22, 2011        
                             
10.4   Convertible Promissory Note between MusclePharm Corporation and Brad J. Pyatt, dated November 18, 2010.   S-1/A   333-176771   4.2   September 27, 2011        
                             
10.5   Convertible Promissory Note between MusclePharm Corporation and Brad J. Pyatt, dated November 23, 2010.   S-1/A   333-176771   4.3   September 27, 2011        
                             
10.6   Amended and Restated Employment Agreement, dated November 14, 2011, between MusclePharm Corporation and Brad J. Pyatt.   10-Q   000-53166   10.6   November 14, 2011        
                             
10.7   Amended and Restated Employment Agreement, dated November 14, 2011, between MusclePharm Corporation and Cory J. Gregory.   10-Q   000-53166   10.7   November 14, 2011        
                             
10.8   Employment Agreement, dated September 15, 2011, by and between MusclePharm Corporation and John H. Bluher.   10-Q   000-53166   10.4   November 14, 2011        
                             
10.9   Employment Agreement, dated November 14, 2011, by and between MusclePharm Corporation and Jeremy R. DeLuca.   10-Q   000-53166   10.5   November 14, 2011        
                             
10.10   Securities Purchase Agreement, dated July 10, 2012, between MusclePharm Corporation and Subscribers set forth therein.   8-K   000-53166   10.1   July 19, 2012        
                             
10.11   Consulting Agreement, dated July 12, 2012, between MusclePharm Corporation and Melechdavid, Inc.   8-K   000-53166   10.2   July 19, 2012        
                             
10.12   Consulting Agreement, dated July 12, 2012, between MusclePharm Corporation and GRQ Consultants, Inc.   8-K   000-53166   10.3   July 19, 2012        
                             
10.13   Form of Committed Equity Facility Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        
                             
10.14   Form of Registration Rights Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        
                             
10.15   Form of Security Agreement, dated July 13, 2012, between MusclePharm Corporation and TCA Global Credit Master Fund LP.   8-K   000-53166   10.1   July 20, 2012        

 

 
 

 

10.16   Form of Indemnification Agreement.   8-K   000-53166   10.1   August 27, 2012        
                             
10.17   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Brad J. Pyatt.   8-K   000-53166   10.1   October 23, 2012        
                             
10.18   Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and L. Gary Davis.   8-K   000-53166   10.2   October 23, 2012        
                             
10.19   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and John H. Bluher.   8-K   000-53166   10.3   October 23, 2012        
                             
10.20   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Jeremy R. DeLuca.   8-K   000-53166   10.4   October 23, 2012        
                             
10.21   Amended and Restated Employment Agreement, dated October 18, 2012, between MusclePharm Corporation and Cory J. Gregory.   8-K   000-53166   10.5   October 23, 2012        
                             
10.22   Form of Restricted Stock Unit Award.   8-K   000-53166   10.1   November 21, 2012        
                             
10.23   Subscription Agreement dated November 30, 2012 between MusclePharm Corporation and the subscribers listed therein.   8-K   000-53166   10.1   December 10, 2012        
                             
10.24   Form of Escrow Agreement.   POS AM   333-184625   10.24   January 8, 2013        
                             
10.25   Form of Subscription Agreement.   8-K   000-53166   10.1   January 28, 2013        
                             
21   Subsidiary of the Registrant.   S-1   333-184625   21   October 26, 2012        
                             
23.1   Consent of Berman & Company, P.A.   POS AM   333-184625   23.1   January 16, 2013        
                             
23.2   Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).   8-K   000-53166   5.1   January 28, 2013        
                             
24.1   Power of Attorney.   S-1/A   333-184625       December 19, 2012        
                             
101.INS   INS XBRL Instance Document.                       X
                             
101.SCH   SCH XBRL Schema Document.                       X
                             
101.CAL   CAL XBRL Calculation Linkbase Document.                       X
                             
101.DEF   DEF XBRL Definition Linkbase Document.                       X
                             
101.LAB   LAB XBRL Label Linkbase Document.                       X
                             
101.PRE   PRE XBRL Presentation Linkbase Document.                       X